Refisolone

Refisolone
Clinical data
Other names	PH-80; PH80; PH-80-M; PH80-M; PH80M; PH80-PMD NS; PH80-HF; PH80-HF NS; Salubrin; Salubrin HF; ORG-39479; ORG39479; 10-Hydroxy-16α,17α-epoxyestr-4-en-3-one; 16α,17α-Epoxyestr-4-en-10-ol-3-one
Routes of; administration	Intranasal (nasal spray)
Drug class	Vomeropherine
Identifiers
	IUPAC name (1S,2S,4R,6S,7S,10S,11S)-11-hydroxy-7-methyl-5-oxapentacyclo[8.8.0.02,7.04,6.011,16]octadec-15-en-14-one;
CAS Number	202718-04-5;
PubChem CID	21968346;
UNII	2QA794326X;
Chemical and physical data
Formula	C18H24O3
Molar mass	288.387 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@@H]4[C@H]2O4)CCC5=CC(=O)CC[C@]35O;
	InChI InChI=1S/C18H24O3/c1-17-6-5-13-12(14(17)9-15-16(17)21-15)3-2-10-8-11(19)4-7-18(10,13)20/h8,12-16,20H,2-7,9H2,1H3/t12-,13+,14+,15-,16-,17+,18-/m1/s1; Key:WLYKLZRFENOYIA-QQNKPZKVSA-N;

Refisolone (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names PH-80, Salubrin, and ORG-39479), also known as 10-hydroxy-16α,17α-epoxyestr-4-en-3-one, is a vomeropherine (pherine) which is under development for the treatment of hot flashes, migraine, and premenstrual dysphoric disorder (PMDD). It is taken intranasally as a nasal spray. The pharmacology of refisolone has been studied and reported. The drug is under development by Pherin Pharmaceuticals and VistaGen Therapeutics, with the former having been acquired by the latter in 2023. As of December 2025, refisolone is in phase 2 clinical trials for all indications. However, a phase 3 trial of refisolone for PMDD is also reported to have been registered in 2015, though its status is listed as unknown.